MyPharmaGenes® PGx
MyPharmaGenes® PGx is a comprehensive pharmacogenetic test for the definition of a personalized pharmacological plan for the treatment of pathologies across different therapeutic areas such as:
- Psychiatry
- Painmanagement
- Oncology
- Diabetes
- Cardiovascular diseases
MyPharmaGenes® PGx is supported by an interactive WebApp that helps the user to manage their medications and to register drugs that have triggered side effects.
At some point in your life, you will take medication. Be informed and avoid side effects.
WHY IS IT IMPORTANT TO ADDRESS PHARMACOGENETICS?
- Variability in drug response constitutes a major public health concern, accounting for 2.5–10.6% of all hospital admissions in the EU [1].
- More than 90% of the drugs are not effective for more than 50% of patients [2,3].
- Approximately 17% of patients are receiving a drug that triggers adverse reactions [4].
- Genetic variants affecting the absorption, distribution, metabolism, excretion, and toxicity of drugs explain around 20–30% of the variability in drug response between individuals [5].
MyPharmaGenes® PGx IS INDICATED FOR:
- Patients who are starting new therapies;
- Patients who are not achieving therapeutic goals and/or experience moderate to severe adverse effects with the current therapy;
- Any person that would like to be informed about their genetic predisposition to respond to certain drugs.
Klicke hier, um Ihren eigenen Text einzufügen
WHAT IS ANALYSED?
The MyPharmaGenes® PGx test analyses genetic variants associated with the metabolism and response to certain drugs, scientifically validated and with proven clinical utility.
MyPharmaGenes® PGx HIGHLIGHTS
- Coverage of more than 100 drugs;
- Evaluation of 32 genes and 88 genetic variants;
- Evaluation of CYP2D6 CNVs and hybrid structures.
Evaluation of CYP2D6 CNVs and hybrid structures is of high importance for the correct definition of a patient phenotype [6]. Without their analysis, the clinical recommendations presented may be misleading what may result in misguided patient care.
Only with the correct evaluation of the patients’ genotypic profile is possible to:
- Prescribe more adequate drug dosages;
- Evaluate the patient response to the treatment;
- Avoid adverse drug reactions;
- Select alternative agents, if necessary.
And, consequently, offer better treatment to more patients.
MyPharmaGenes® PGx PANEL
32 Genes
ABCB1, ABCG2, APOE, C11orf65, COMT, CYP1A2, CYP2B6, CYP2C18, CYP2C19, CYP2C8, CYP2C9, CYP2D6, CYP3A4, CYP3A5, DPYD, DRD2, F2, F5, GSTP1, HLA-A, HLA-B, HTR2A, HTR2C, MC4R, MTHFR, NUDT15, OPRM1, SLCO1B1, TCF7L2, TPMT, UGT1A1, VKORC1
DRUGS EVALUATED BY THERAPEUTIC AREA
Psychiatry
Amisulpride, Amitriptyline, Amphetamine, Aripiprazole, Atomoxetine, Brexpiprazole, Brivaracetam, Carbamazepine, Citalopram, Clobazam, Clomipramine, Clozapine, Desipramine, Diazepam, Donepezil, Doxepin, Escitalopram, Fluoxetine, Fluvoxamine, Galantamine, Haloperidol, Iloperidone, Imipramine, Mirtazapine, Nortriptyline, Olanzapine, Oxcarbazepine, Paliperidone, Paroxetine, Perphenazine, Phenytoin, Pimozide, Quetiapine, Risperidone, Sertraline, Tetrabenazine, Trimipramine, Venlafaxine, Vortioxetine, Ziprasidone
Pain Management
Oncology
Diabetes
Cardiovascular
AN INTERACTIVE WEBAPP
MyPharmaGenes® PGx is supported by an interactive WebApp where patients can:
- Manage their own drug portfolio;
- Register drugs that have triggered side effects;
- Have rapid access to which drugs may or may not be recommended for them;
- Find more specific information regarding the genes evaluated.
INTERNATIONAL GUIDELINES AND DRUG LABEL ANNOTATIONS
MyPharmaGenes® PGx is in-line with the recommendations provided by international pharmacogenetics consortia (CPIC, DPWG and CPNDS) that develop peer-reviewed gene-drug guidelines that are published and updated periodically based on new developments across several fields of medicine, as well as by several drug agencies (FDA, EMA, Health Canada, PMDA Japan and Swissmedic).
SCIENTIFIC STUDIES
[1] Bouvy, J.C., De Bruin, M.L. & Koopmanschap, M.A. “Epidemiology of Adverse Drug Reactions in Europe: A Review of Recent Observational Studies”. Drug Saf 38 (2015): 437–453.
[2] Steve Connor (2003) “Glaxo chief: Our drugs do not work on most patients”, Independent/UK, 8/12/2003.
[3] Spear, B.B., Heath-Chiozzi, M. & Huff, J., “Clinical Application of Pharmacogenetics”. Trends Mol Med 7.5 (2001):201-204.
[4] Böhm, R. & Cascorbi, I., “Pharmacogenetics and Predictive Testing of Drug Hypersensitivity Reactions”. Front Pharmacol 7 (2016): 396.
[5] Lauschke, V.M., Milani, L. & Ingelman-Sundberg, M. “Pharmacogenomic Biomarkers for Improved Drug Therapy—Recent Progress and Future Developments”. AAPS J 20.1 (2018): 4.
[6] Gaedigk, Andrea, et al. “Characterization of Reference Materials for Genetic Testing of CYP2D6 Alleles: A GeT-RM Collaborative Project”. J Mol Diagn 21.6 (2019): 1034-1052.
[2] Steve Connor (2003) “Glaxo chief: Our drugs do not work on most patients”, Independent/UK, 8/12/2003.
[3] Spear, B.B., Heath-Chiozzi, M. & Huff, J., “Clinical Application of Pharmacogenetics”. Trends Mol Med 7.5 (2001):201-204.
[4] Böhm, R. & Cascorbi, I., “Pharmacogenetics and Predictive Testing of Drug Hypersensitivity Reactions”. Front Pharmacol 7 (2016): 396.
[5] Lauschke, V.M., Milani, L. & Ingelman-Sundberg, M. “Pharmacogenomic Biomarkers for Improved Drug Therapy—Recent Progress and Future Developments”. AAPS J 20.1 (2018): 4.
[6] Gaedigk, Andrea, et al. “Characterization of Reference Materials for Genetic Testing of CYP2D6 Alleles: A GeT-RM Collaborative Project”. J Mol Diagn 21.6 (2019): 1034-1052.